Overall survival data from Array BioPharma Inc.'s Phase III BEACON CRC safety lead-in trial of its BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and Eli Lilly & Co./Merck KGaA's anti-EGFR antibody Erbitux (cetuximab) suggest the triplet combination could prove valuable as a treatment for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Array reported at the European Society of Medical Oncology's gastrointestinal cancer conference (ESMO-GI) in Barcelona June 23 that the combo...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

